Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Authors:
Open Access
- 16 July 2016
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 33 (9) , 1502-1518
Abstract
Blood glucose-lowering treatment options generally target insulin action or beta-cell function. In diabetes, expression of the sodium-glucose cotransporter-2 (SGLT2) genes is up-regulated and renal threshold increased, resulting in increased glucose reabsorption from glomerular filtrate, reducing urinary glucose excretion and worsening the hyperglycemic condition. The SGLT2 inhibitors (SGLT2i) are a novel class of anti-diabetic drugs that lower blood glucose levels through the suppression of renal glucose reabsorption thereby promoting renal glucose excretion. The efficacy of SGLT2i is reduced in renal impairment because the ability of glucose-lowering is directly proportional to glomerular filtration rate. On the other hand, ongoing research suggests that SGLT2i may offer potential nephroprotection in diabetes. The SGLT2i have been shown to reduce glomerular hyperfiltration, systemic and intraglomerular pressure and the biochemical progression of chronic kidney disease. Additional mechanisms through which SGLT2i exert nephroprotection may include normalizing blood pressure and uricemia. This review explores this bidirectional relationship of the SGLT2i and the glomerulus. While SGLT2i exhibit reduced efficacy in later stages, they exhibit nephroprotective effects in early stages of renal impairment. Funding: Janssen India (Pharmaceutical division of Johnson & Johnson).Keywords
Funding Information
- Janssen
This publication has 81 references indexed in Scilit:
- SGLT-2 inhibitors and their potential in the treatment of diabetesDiabetes, Metabolic Syndrome and Obesity, 2013
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes, Obesity and Metabolism, 2013
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?PLOS ONE, 2013
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- Renal hyperfiltration related to diabetes mellitus and obesity in human diseaseWorld Journal of Diabetes, 2012
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With MetforminDiabetes Care, 2011
- Impaired Fasting Glucose Is Associated With Renal Hyperfiltration in the General PopulationDiabetes Care, 2011
- Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and ManagementAdvances in Chronic Kidney Disease, 2011
- Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular RiskClinical Journal of the American Society of Nephrology, 2010
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010